PT-141 vs Melanotan II: Receptor Pharmacology and Research Models
PT-141, also known as bremelanotide, and Melanotan II (MT-II or MT-2) are related synthetic cyclic peptides studied as melanocortin receptor agonists. A useful laboratory comparison separates chemical identity, receptor binding, functional signaling, and model-specific observations. These are different levels of evidence and should not be treated as interchangeable.
This article examines that distinction for nonclinical laboratory researchers. The linked PT-141 and Melanotan II catalog entries identify materials offered by Alpha Carbon Labs solely for nonclinical laboratory research; published studies discussed here are not tests of those products.
Chemical Relationship and Receptor Selectivity
PT-141 and Melanotan II are structurally related, but they are not identical compounds. PT-141 is the C-terminal carboxylic-acid analogue of Melanotan II, which has a C-terminal amide. This distinction should be reflected in identity testing and reference-material selection. A shared peptide scaffold does not establish identical pharmacology, stability, or analytical behavior.
The description of PT-141 as an almost exclusively MC4R-selective compound with negligible MC1R affinity is not an appropriate basis for this comparison. Neither compound should be treated as an MC4R-exclusive probe. A structural difference alone also does not establish a particular magnitude or direction of receptor selectivity.
Melanocortin receptors comprise five subtypes, MC1R through MC5R. Receptor selectivity is a comparative measurement, not a label that can be inferred from a compound's name or a whole-organism endpoint. Researchers should distinguish binding affinity from functional potency and efficacy, and specify the receptor subtype, species, expression system, and endpoint for each comparison.
What the Supplied Literature Can Establish
The citation list contains human studies, a female-rat study, and reviews. It does not provide a matched, quantitative in-vitro receptor panel or an in-silico comparison from which to calculate a PT-141-versus-Melanotan II selectivity ranking. Clinical observations, animal behavior, receptor assays, and computational predictions answer different questions.
Human Studies: Population-Specific Evidence
Diamond et al. examined PT-141 in healthy male participants and men with mild-to-moderate erectile dysfunction, while Rosen et al. examined healthy male participants and men with an inadequate response to Viagra. These human studies addressed safety, pharmacokinetic, and pharmacodynamic endpoints under their respective study conditions.[1,9] They are not isolated receptor-subtype experiments and do not establish the properties of Alpha Carbon Labs material.
Kingsberg et al. reported two randomized phase 3 trials of bremelanotide in premenopausal women with hypoactive sexual desire disorder.[4] Nausea, flushing, and headache were reported adverse events in that human study population. These observations should not be minimized as universally mild or used to infer a safety profile for a laboratory reagent.
The Melanotan II references include Dorr et al.'s pilot phase-I study in human volunteers and Wessells et al.'s double-blind, placebo-controlled crossover study in men with psychogenic erectile dysfunction.[7,5] These human investigations should not be presented as a head-to-head comparison with PT-141 or as direct measurements of receptor affinity, receptor occupancy, or blood-brain barrier penetration.
Animal Evidence: A Defined Behavioral Model
Pfaus et al. investigated a melanocortin receptor agonist using sexual-solicitation behavior in female rats.[6] This is an animal behavioral model, not a measurement of human subjective experience. A behavioral endpoint alone cannot quantify affinity across melanocortin receptor subtypes or establish equivalent responses in other species.
Reviews: Background Rather Than a Matched Dataset
Shadiack et al., Hadley and Dorr, Schiöth, and Wikberg provide review-level discussions of melanocortin pharmacology, physiology, or development history.[2,3,8,10] These reviews are not a single experimental model or study population. For a model-specific claim, researchers should identify the underlying primary experiment rather than assign a review-wide conclusion to a particular receptor assay, animal model, or human population.
A Laboratory Comparison Framework
| Comparison dimension | PT-141 | Melanotan II | Interpretive requirement |
|---|---|---|---|
| Chemical identity | Also called bremelanotide; C-terminal carboxylic-acid analogue | Related cyclic peptide with a C-terminal amide | Use the correct molecular identity and document the supplied chemical form. |
| Receptor selectivity | Do not assume exclusive MC4R activity. | Do not assign a receptor ranking from organism-level observations. | Compare subtype-specific measurements obtained under matched conditions. |
| Functional activity | Requires a defined assay endpoint. | Requires the same endpoint for a direct comparison. | Report potency and maximal response separately from binding affinity. |
| Published human evidence | Human populations are described in references 1, 4, and 9. | Human populations are described in references 5 and 7. | Do not pool distinct populations and protocols into a comparative performance claim. |
| Supplier material | Requires lot-specific analytical documentation. | Requires lot-specific analytical documentation. | A literature citation does not characterize a commercial lot. |
Designing and Interpreting Nonclinical Assays
For an in-vitro receptor comparison, document the receptor species and subtype, host-cell background, expression conditions, readout, controls, and analysis method. Binding assays address ligand-receptor interaction; functional assays address a selected signaling response. Values from different assay formats should not be combined into a selectivity ratio without evaluating whether their methods are comparable.
- Separate potency and efficacy: A change in functional potency is not automatically a change in binding affinity or maximal response.
- Control the experimental background: Include appropriate vehicle, reference, and receptor-negative controls where applicable.
- Check assay interference: Evaluate whether compound degradation, background signal, or effects on cell viability could alter the readout.
- Keep endpoint claims narrow: A cellular signal does not establish brain exposure, and an animal behavioral observation does not identify a single responsible receptor without additional mechanistic evidence.
- Separate computational and experimental evidence: A docking score or predicted interaction, if generated in a separate project, is not a measured affinity or demonstrated biological response. No compound-specific in-silico result is supplied here.
These are considerations for experimental design, not reported comparative results for the two compounds. No numerical affinity, potency, selectivity ratio, or comparative stability value is supplied in this article.
Analytical Documentation and Laboratory Handling
Review lot-specific Certificates of Analysis alongside the methods described in the quality-control documentation. Confirm that the document corresponds to the material and lot under study. Relevant information includes the stated chemical form, identity method, chromatographic method, and the basis of any purity or content result.
High-performance liquid chromatography can characterize chromatographic purity under a defined method, while mass spectrometry can support molecular-identity assessment. A chromatographic area percentage is not automatically peptide mass content, and a matching mass alone does not establish complete structural identity. Neither measurement alone establishes sterility, absence of all contaminants, or biological activity.
General information about peptide synthesis can help researchers understand manufacturing and purification methods, but it does not replace batch-specific evidence. The supplied article provides no verified lot-specific specification, validated storage condition, or stability dataset for either Alpha Carbon Labs product. Accordingly, no universal purity threshold or handling condition is asserted here.
Before laboratory work, consult the applicable safety data sheet, product documentation, and institutional risk assessment. Use appropriate exposure controls, personal protective equipment, and chemical-waste procedures. Human adverse-event reports do not substitute for a laboratory hazard assessment, and incomplete hazard information should not be interpreted as evidence of low risk.
References
- Diamond, L. E., Earle, D. C., Rosen, R. C., et al. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16(1), 51-59. — https://pubmed.ncbi.nlm.nih.gov/14963471/
- Shadiack, A. M., Sharma, S. D., Earle, D. C., et al. (2007). Melanocortins in the treatment of male and female sexual dysfunction. Current Topics in Medicinal Chemistry, 7(11), 1137-1144. — https://pubmed.ncbi.nlm.nih.gov/17584134/
- Hadley, M. E., & Dorr, R. T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921-930. — https://pubmed.ncbi.nlm.nih.gov/16412534/
- Kingsberg, S. A., Clayton, A. H., Portman, D., et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology, 134(5), 899-908. — https://pubmed.ncbi.nlm.nih.gov/31599840/
- Wessells, H., Fuciarelli, K., Hansen, J., et al. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. The Journal of Urology, 160(2), 389-393. — https://pubmed.ncbi.nlm.nih.gov/9679884/
- Pfaus, J. G., Shadiack, A., Van Soest, T., et al. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences, 101(27), 10201-10204. — https://pubmed.ncbi.nlm.nih.gov/15232007/
- Dorr, R. T., Lines, R., Levine, N., et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777-1784. — https://pubmed.ncbi.nlm.nih.gov/8637402/
- Schiöth, H. B. (2001). The physiological role of melanocortin receptors. Vitamins and Hormones, 63, 195-232. — https://pubmed.ncbi.nlm.nih.gov/11358116/
- Rosen, R. C., Diamond, L. E., Earle, D. C., et al. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research, 16(2), 135-142. — https://pubmed.ncbi.nlm.nih.gov/14999221/
- Wikberg, J. E. (1999). Melanocortin receptors: perspectives for novel drugs. European Journal of Pharmacology, 375(1-3), 295-310. — https://pubmed.ncbi.nlm.nih.gov/10443584/
Limitations
Evidence is specific to the material, model, population, and methods studied. Published findings do not establish the safety, effectiveness, approval, or suitability of material sold by Alpha Carbon Labs for human or veterinary use. These materials are intended solely for nonclinical laboratory research.